Anuh Pharma Ltd Q1 FY26 Results & Presentation Highlights: Revenue ₹186.48 Cr, PAT ₹8.30 Cr

The investor presentation does not explicitly mention any specific capex, capacity expansion, or new plant/project details such as amounts, status, or timelines. It highlights: - Ongoing investments in compliance, manufacturing efficiency, and product pipeline expansion, particularly in regulated markets (Page 7). - Infrastructure includes modern manufacturing facilities equipped with Zero Liquid Discharge Effluent Control, green belt, 100% power backup, and advanced safety measures (Page 31). - No explicit figures or timelines for capex or new plant projects are disclosed. Thus, while there is mention of ongoing investments aimed at growth and efficiency, no detailed capex plans, capacity expansions, or new plant projects with financials or schedules are provided in this presentation.

The investor presentation does not explicitly report any details on: - Order book value - Order inflow - Pending orders No specific figures or qualitative information regarding current order backlog or inflow are mentioned in the document. The presentation focuses primarily on financial performance, business outlook, shareholding pattern, infrastructure, management, and CSR activities but does not disclose order book statistics.